{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:00:21Z","timestamp":1769752821954,"version":"3.49.0"},"reference-count":135,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1080\/14712598.2020.1819978","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T22:15:47Z","timestamp":1599171347000},"page":"145-160","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors"],"prefix":"10.1080","volume":"21","author":[{"given":"Varada","family":"Date","sequence":"first","affiliation":[{"name":"Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM\u2019s NMIMS University, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-7375","authenticated-orcid":false,"given":"Sujit","family":"Nair","sequence":"additional","affiliation":[{"name":"SVKM\u2019s Dr. Bhanuben Nanavati College of Pharmacy, University of Mumbai, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"cit0002","unstructured":"Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah\u2122 (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice novartis [Online]; 2017. Available from: https:\/\/novartis.gcs-web.com\/novartis-receives-fda-approval-for-KymriahTM"},{"key":"cit0003","unstructured":"Institute NC. Tisagenlecleucel (Kymriah) approved to treat some lymphomas; 2018 [cited 2019 Jul 22]. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/tisagenlecleucel-fda-lymphoma"},{"key":"cit0004","unstructured":"Gilead. Kite\u2019s Yescarta\u2122 (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy gilead [Online]; 2017. Available from: http:\/\/www.gilead.com\/news\/press-releases\/2017\/10\/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy"},{"key":"cit0005","unstructured":"Novartis. Novartis receives European commission approval of its CAR-T cell therapy, Kymriah\u00ae (tisagenlecleucel) novartis. [Online]; 2018. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel"},{"key":"cit0006","unstructured":"Gilead. Yescarta\u00ae (Axicabtagene Ciloleucel) receives european marketing authorization for the treatment of relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy | gilead. [Online]; 2018. Available from: http:\/\/www.gilead.com\/news\/press-releases\/2018\/8\/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy"},{"key":"cit0007","unstructured":"Novartis.ca. Novartis receives health Canada approval of its CAR-T cell therapy, Kymriah\u2122 (tisagenlecleucel) novartis Canada. [Online]. Available from: https:\/\/www.novartis.ca\/en\/news\/media-releases\/novartis-receives-health-canada-approval-its-car-t-cell-therapy-kymriah"},{"key":"cit0008","unstructured":"Pmda; 2019 [cited 2019 Jul 17]. Available from: http:\/\/www.pmda.go.jp\/files\/000230002.pdf#page=1\u200e"},{"key":"cit0009","unstructured":"TGA. Search the TGA website; 2019 [cited 2019 Jul 17]. Available from: http:\/\/search.tga.gov.au\/s\/search.html?collection=tga-artg&profile=record&meta_i=312686"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-018-9756-5"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-018-0409-x"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124844"},{"issue":"7","key":"cit0013","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","volume":"12","author":"Cornel AM","year":"2020","journal-title":"Cancers (Basel)"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12131"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12126"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2018.0037"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2015.11.004"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2018.1430465"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.7.4901"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000161397.96582.59"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.573476"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90314-O"},{"issue":"6","key":"cit0023","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","volume":"161","author":"Finney HM","year":"1998","journal-title":"J Iimmunol"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.104"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.122"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25960"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12125"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044"},{"key":"cit0032","unstructured":"Clinicaltrials.gov. Search of: fourth generation CAR - list results - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=fourth+generation+CAR&cntry=&state=&city=&dist="},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2013.144"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4258"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5222"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0817-0"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839217"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2018.01.025"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.10.012"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0715-9"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0646-9"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9689-9"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01717"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00493"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1342909"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1473368"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006597"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.012"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.011"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1149-9"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094281"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5964"},{"issue":"2","key":"cit0061","first-page":"1","volume":"17","author":"Gulati I","year":"2020","journal-title":"Curr Pharmacogenomics Pers Med"},{"issue":"399","key":"cit0062","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"O\u2019Rourke DM","year":"2017","journal-title":"Sci Transl Med"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082742"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00507"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015230"},{"key":"cit0067","unstructured":"Clinicaltrials.gov. Search of: caspase 9 CAR T-cells - list results - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=caspase+9+CAR+T-cells&cntry=&state=&city=&dist="},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802926"},{"key":"cit0069","unstructured":"Clinicaltrials.gov. iC9-GD2-CAR-VZV-CTLs\/refractory or metastatic GD2-positive sarcoma and neuroblastoma - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01953900?term=NCT01953900&draw=2&rank=1."},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01104"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02103"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.4161\/21505594.2014.988098"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0314"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0351"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050674"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010162"},{"key":"cit0080","author":"Rusch VW","year":"2019","journal-title":"Cancer Res"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02268"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0222-9"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0340-z"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2041"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0428"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.10.002"},{"key":"cit0087","unstructured":"Clinicaltrials.gov. Phase I trial: T4 immunotherapy of head and neck cancer - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01818323?term=NCT01818323&draw=2&rank=1"},{"key":"cit0088","unstructured":"Clinicaltrials.gov. Search of: regional delivery CAR T-cells - list results - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Regional+delivery+CAR+T-cells&cntry=&state=&city=&dist="},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00310-6"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0263"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-017-0543-6"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15218"},{"key":"cit0094","unstructured":"Clinicaltrials.gov. NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T cells (NYCE T cells) - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03399448?term=NCT03399448&draw=2&rank=1"},{"key":"cit0095","unstructured":"Clinicaltrials.gov. Study of PD-1 gene-knocked out mesothelin-directed CAR-T cells with the conditioning of PC in mesothelin positive multiple solid tumors - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03747965?term=NCT03747965&draw=2&rank=1"},{"key":"cit0096","unstructured":"Clinicaltrials.gov. Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors. full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03545815?term=NCT03545815&draw=2&rank=1"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.06.035"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9114"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458"},{"key":"cit0100","unstructured":"Clinicaltrials.gov. IL13Ralpha2-targeted Chimeric Antigen Receptor (CAR) T cells with or without nivolumab and ipilimumab in treating patients with recurrent or refractory glioblastoma - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04003649?term=NCT04003649&draw=2&rank=1"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.08.002"},{"key":"cit0102","unstructured":"Clinicaltrials.gov. Autologous T cells redirected to EGFRVIII-with a chimeric antigen receptor in patients with EGFRVIII+ glioblastoma - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02209376?term=NCT02209376&draw=1&rank=1"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1142"},{"key":"cit0104","unstructured":"Clinicaltrials.gov. Search of: immune checkpoint expressing CAR - list results - ClinicalTrials.gov. [Online]; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=immune+checkpoint+expressing+CAR&cntry=&state=&city=&dist="},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2524"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12350"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401710"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.014"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-127"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26532"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.110"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-615"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130110"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1298"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020121"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317695021"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89455"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0502"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.7150\/thno.29431"},{"key":"cit0122","unstructured":"Fda.gov. Precision medicine. [Online]; 2018. Available from: https:\/\/www.fda.gov\/MedicalDevices\/ProductsandMedicalProcedures\/InVitroDiagnostics\/PrecisionMedicine-MedicalDevices\/default.htm"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-018-0139-0"},{"key":"cit0124","unstructured":"Allofus.nih.gov. Program overview - all of us national institutes of health. [Online]; 2018. Available from: https:\/\/allofus.nih.gov\/about\/about-all-us-research-program"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.2217\/pme-2016-0108"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau4580"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0977"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S146309"},{"key":"cit0129","unstructured":"England N. NHS England NHS England announces groundbreaking new personalised therapy for children with cancer. [Online]. England.nhs.uk; 2018. Available from: https:\/\/www.england.nhs.uk\/2018\/09\/nhs-england-announces-groundbreaking-new-personalised-therapy-for-children-with-cancer\/"},{"key":"cit0130","unstructured":"England N. NHS England NHS England strikes deal for ground breaking cancer treatment in a new European first. [Online]. England.nhs.uk; 2018. Available from: https:\/\/www.england.nhs.uk\/2018\/10\/nhs-england-strikes-deal-for-ground-breaking-cancer-treatment-in-a-new-european-first\/"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"cit0133","unstructured":"clinicaltrials.gov. alloSHRINK - standard chemotherapy regimen and immunotherapy with allogeneic NKG2D-based CYAD-101 chimeric antigen receptor t-cells - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03692429"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105695"},{"key":"cit0135","unstructured":"Clinicaltrials.gov. Search of: CAR T cell therapy cancer - list results - ClinicalTrials.gov. [Online]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=cancer&term=CAR+T+Cell+therapy&cntry=&state=&city=&dist="}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2020.1819978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T21:06:35Z","timestamp":1696626395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2020.1819978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1080\/14712598.2020.1819978"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2020.1819978","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}